The PRO-ACT database: design, initial analyses, and predictive features

To pool data from completed amyotrophic lateral sclerosis (ALS) clinical trials and create an open-access resource that enables greater understanding of the phenotype and biology of ALS. Clinical trials data were pooled from 16 completed phase II/III ALS clinical trials and one observational study....

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Neurology Jg. 83; H. 19; S. 1719
Hauptverfasser: Atassi, Nazem, Berry, James, Shui, Amy, Zach, Neta, Sherman, Alexander, Sinani, Ervin, Walker, Jason, Katsovskiy, Igor, Schoenfeld, David, Cudkowicz, Merit, Leitner, Melanie
Format: Journal Article
Sprache:Englisch
Veröffentlicht: United States 04.11.2014
Schlagworte:
Amyotrophic Lateral Sclerosis - diagnosis
Amyotrophic Lateral Sclerosis - physiopathology
Amyotrophic Lateral Sclerosis - therapy
Clinical Trials as Topic - statistics & numerical data
Database Management Systems
Datasets as Topic - statistics & numerical data
Disease Progression
Humans
Longitudinal Studies
Observational Studies as Topic - statistics & numerical data
Predictive Value of Tests
Research Design
ISSN:1526-632X, 1526-632X
Online-Zugang:Weitere Angaben
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:To pool data from completed amyotrophic lateral sclerosis (ALS) clinical trials and create an open-access resource that enables greater understanding of the phenotype and biology of ALS. Clinical trials data were pooled from 16 completed phase II/III ALS clinical trials and one observational study. Over 8 million de-identified longitudinally collected data points from over 8,600 individuals with ALS were standardized across trials and merged to create the Pooled Resource Open-Access ALS Clinical Trials (PRO-ACT) database. This database includes demographics, family histories, and longitudinal clinical and laboratory data. Mixed effects models were used to describe the rate of disease progression measured by the Revised ALS Functional Rating Scale (ALSFRS-R) and vital capacity (VC). Cox regression models were used to describe survival data. Implementing Bonferroni correction, the critical p value for 15 different tests was p = 0.003. The ALSFRS-R rate of decline was 1.02 (±2.3) points per month and the VC rate of decline was 2.24% of predicted (±6.9) per month. Higher levels of uric acid at trial entry were predictive of a slower drop in ALSFRS-R (p = 0.01) and VC (p < 0.0001), and longer survival (p = 0.02). Higher levels of creatinine at baseline were predictive of a slower drop in ALSFRS-R (p = 0.01) and VC (p < 0.0001), and longer survival (p = 0.01). Finally, higher body mass index (BMI) at baseline was associated with longer survival (p < 0.0001). The PRO-ACT database is the largest publicly available repository of merged ALS clinical trials data. We report that baseline levels of creatinine and uric acid, as well as baseline BMI, are strong predictors of disease progression and survival.
Bibliographie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1526-632X
1526-632X
DOI:10.1212/WNL.0000000000000951